Silke Bruderlein
Overview
Explore the profile of Silke Bruderlein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
695
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bohm M, Marienfeld R, Jager D, Mellert K, von Witzleben A, Bruderlein S, et al.
Sarcoma
. 2019 Feb;
2019:3914232.
PMID: 30804704
Leiomyosarcoma (LMS) is characterized by high genomic complexity, and to date, no specific targeted therapy is available. In a genome-wide approach, we profiled genomic aberrations in a small cohort of...
2.
Jager D, Barth T, Bruderlein S, Scheuerle A, Rinner B, von Witzleben A, et al.
Sci Rep
. 2017 May;
7(1):2032.
PMID: 28515451
Chordomas are rare tumours of the bone arising along the spine from clivus to sacrum. We compared three chordoma cell lines of the clivus region including the newly established clivus...
3.
Zahn M, Marienfeld R, Melzner I, Heinrich J, Renner B, Wegener S, et al.
Blood
. 2017 Jan;
129(11):1480-1490.
PMID: 28082443
Chronic activation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathways is a hallmark of a variety of B-cell lymphomas, including classical Hodgkin lymphoma (cHL). Constitutive...
4.
Scheipl S, Barnard M, Cottone L, Jorgensen M, Drewry D, Zuercher W, et al.
J Pathol
. 2016 Apr;
239(3):320-34.
PMID: 27102572
Chordoma is a rare malignant bone tumour with a poor prognosis and limited therapeutic options. We undertook a focused compound screen (FCS) against 1097 compounds on three well-characterized chordoma cell...
5.
von Witzleben A, Goerttler L, Marienfeld R, Barth H, Lechel A, Mellert K, et al.
Cancer Res
. 2015 Jul;
75(18):3823-31.
PMID: 26183925
Chordomas are tumors that arise at vertebral bodies and the base of the skull. Although rare in incidence, they are deadly owing to slow growth and a lack of effective...
6.
Dinges H, Capper D, Ritz O, Bruderlein S, Marienfeld R, von Deimling A, et al.
Appl Immunohistochem Mol Morphol
. 2015 Jan;
23(5):382-8.
PMID: 25611237
Detection of BRAF V600E has diagnostic, prognostic, and therapeutic relevance. The recently developed BRAF V600E mutation-specific antibody has evolved into a feasible alternative to DNA analysis. The plethora of immunohistochemical...
7.
Bubolz A, Weissinger S, Stenzinger A, Arndt A, Steinestel K, Bruderlein S, et al.
Oncotarget
. 2014 Jun;
5(12):4060-70.
PMID: 24938183
For a growing number of tumors the BRAF V600E mutation carries therapeutic relevance. In histiocytic proliferations the distribution of BRAF mutations and their relevance has not been clarified. Here we...
8.
Steinestel K, Bruderlein S, Lennerz J, Steinestel J, Kraft K, Propper C, et al.
Mol Cancer
. 2014 Jun;
13:145.
PMID: 24913355
Background: The Abelson tyrosine kinase (c-Abl) inhibitor STI571 (Glivec®) has been shown to effectively inhibit colorectal cancer cell migration and invasion. The c-Abl substrate abelson interactor 1 (Abi1) is a...
9.
Scheil-Bertram S, Kappler R, von Baer A, Hartwig E, Sarkar M, Serra M, et al.
Int J Oncol
. 2014 Jan;
44(4):1041-55.
PMID: 24452533
The molecular basis of chordoma is still poorly understood, particularly with respect to differentially expressed genes involved in the primary origin of chordoma. In this study, therefore, we compared the...
10.
Ritz O, Rommel K, Dorsch K, Kelsch E, Melzner J, Buck M, et al.
Oncotarget
. 2013 Jul;
4(7):1093-102.
PMID: 23852366
Primary mediastinal B-cell lymphoma (PMBL) is characterized by aberrant activation of JAK/STAT-signaling resulting in constitutive presence of phosphorylated STAT6 (pSTAT6). In primary PMBL samples pSTAT6 is only expressed in a...